Corient Capital Partners’s Bio-Techne TECH Stock Holding History

Corient Capital Partners’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.09M	Buy	12,564 +32	+0.3%	+$2.77K	0.08%	206
2022 Q2	$1.09M	Sell	12,532 -244	-2%	-$22.9K	0.08%	208
2022 Q1	$1.38M	Buy	12,776 +2,068	+19%	+$213K	0.09%	192
2021 Q4	$1.39M	Buy	10,708 +5,088	+91%	+$624K	0.09%	196
2021 Q3	$681K	Buy	5,620 +672	+14%	+$81.8K	0.05%	290
2021 Q2	$557K	Buy	4,948 +924	+23%	+$97.3K	0.04%	334
2021 Q1	$384K	Buy	+4,024	New	+$367K	0.03%	379

Other funds holding TECH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

Corient Capital Partners's TECH Position: Q3 2022 in Review

Corient Capital Partners increased its Bio-Techne (TECH) stake by 0.26% in Q3 2022, buying an estimated $2.77K and bringing the position to 12,564 shares worth $1.09M. The position accounts for 0.08% of the portfolio, ranked #206.

Corient Capital Partners first reported a position in TECH in Q1 2021 and has held it in 7 quarters since. The position peaked at $1.39M in Q4 2021. 535 funds tracked by Wall St. Rank hold TECH as of Q3 2022.

Corient Capital Partners held 12,564 shares of Bio-Techne worth $1.09M as of Q3 2022.
Corient Capital Partners bought 32 Bio-Techne shares in Q3 2022, an estimated $2.77K.
Bio-Techne made up 0.08% of Corient Capital Partners's portfolio in Q3 2022, its #206 holding.
Corient Capital Partners first reported a position in Bio-Techne in Q1 2021 and has held it in 7 quarters since.
Corient Capital Partners's Bio-Techne position peaked at $1.39M in Q4 2021.
535 funds tracked by Wall St. Rank held Bio-Techne as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.